Tesofensine

What it is

Tesofensine is the oral weight-loss drug that produced roughly twice the weight loss of the obesity drugs available at the time — in a Phase 2 trial back in 2008 — and then stalled before crossing the finish line. It’s worth knowing for two reasons: it’s a genuinely different mechanism from the GLP-1 wave everyone’s talking about, and it’s oral, not injectable. For anyone who wants the appetite-and-metabolism lever without a weekly subcutaneous shot, tesofensine is the most-studied non-GLP-1 candidate in that lane.

Be clear on what it is, though: tesofensine is not a peptide. It’s a small-molecule drug — a triple monoamine reuptake inhibitor. It blocks the reabsorption of serotonin, noradrenaline (norepinephrine), and dopamine in the brain, which is the same general pharmacological family as antidepressants and stimulants, not the receptor-agonist biology of the GLP-1 peptides. It earns its place in this branch because it’s part of the same fat-loss decision the GLP-1 articles cover, and OHM readers comparing options deserve the honest cross-class picture.

It started life as NS 2330, a NeuroSearch compound developed for Parkinson’s and Alzheimer’s disease. It didn’t work well enough in either neurological indication — but in those trials, patients reliably lost weight. That side effect became the main event. The obesity program (Phase 2, Astrup et al. 2008) is what tesofensine is known for today. The Danish biotech Saniona now holds it, and has been developing it as a combination tablet (Tesomet) that pairs tesofensine with a low dose of the beta-blocker metoprolol specifically to blunt the cardiovascular side effect that held the standalone drug back.

How it works

One mechanism, three neurotransmitters. Tesofensine inhibits the reuptake transporters for serotonin, noradrenaline, and dopamine — so all three monoamines linger longer in the synapse and their signaling is amplified. (In pharmacology shorthand, that’s an SNDRI: serotonin-noradrenaline-dopamine reuptake inhibitor.) Each of the three is tied to appetite, food-seeking, and energy regulation, so raising all three at once is a broad push on the brain’s eating circuitry. This is fundamentally different from the GLP-1 mechanism (Tirzepatide, Retatrutide), which works through gut-hormone receptor agonism, not monoamine reuptake.

The downstream effects that show up in the human data:

• Reduced appetite + increased satiety. The dominant driver. In the energy-metabolism study (Sjödin et al. 2010, n=32, 14 days), tesofensine raised ratings of satiety and fullness and lowered prospective food intake vs placebo (PMID 20479765). Most of the weight loss is eating less, not burning dramatically more.
• Modest metabolic / fat-oxidation effect. Same study: no significant 24-hour total energy-expenditure change, but nighttime energy expenditure rose ~4.6% and 24-hour fat oxidation increased by ~18 g vs placebo (PMID 20479765). A real but secondary lever.
• Dopaminergic drive + cognitive stimulation. Because it raises dopamine and noradrenaline, tesofensine has a genuine CNS-stimulant character — this is the basis for its secondary “mind” effect (alertness, drive) and also for its primary liability (see below). It’s not a calm appetite suppressant; it’s an activating one.

The signature liability is cardiovascular, and it’s mechanistic, not incidental. Raising noradrenaline and dopamine system-wide nudges heart rate and blood pressure up. In the obesity trials, doses of 0.25–1.0 mg/day produced a blood-pressure rise of about 1–5 mmHg and a heart-rate rise of up to 8 bpm. That sounds small, and at the individual level it often is — but it’s the reason Saniona decided not to develop tesofensine as a standalone drug, and instead built the Tesomet combination, adding the beta-blocker metoprolol specifically to counteract the heart-rate/blood-pressure rise. Knowing why metoprolol is in the combo tells you exactly where tesofensine’s risk lives.

What the research shows

Tesofensine has a real human evidence base — multiple Phase 2 RCTs — but note the ceiling: it never advanced past Phase 2 in obesity. No large Phase 3 program, no FDA approval. The data below is genuine and verified, but it’s mid-stage data, not the confirmatory-trial tier the approved GLP-1s have.

Obesity — the headline result (PMID 18950853, Astrup et al., Lancet 2008):

• Phase 2 RCT, n=203, 24 weeks, four arms (placebo, 0.25 mg, 0.5 mg, 1.0 mg once daily), all on a modest diet.
• Placebo-subtracted weight loss: 0.25 mg → 4.5%; 0.5 mg → 9.2%; 1.0 mg → 10.6% (all p<0.0001).
• The authors’ framing: tesofensine 0.5 mg “might have the potential to produce a weight loss twice that of currently approved drugs” (the comparison was to the 2008-era obesity drugs, i.e. sibutramine — not to today’s GLP-1s).
• A companion Danish secondary publication (Nielsen et al. 2009, n=203, same trial) reported the 0.5–1.0 mg arms at 9–11% greater than placebo (PMID 19824222).

Appetite + energy metabolism mechanism (PMID 20479765, Sjödin et al. 2010): n=32 overweight/obese men, 14 days. ~1.8 kg weight-loss advantage over placebo, driven mainly by appetite suppression plus the modest fat-oxidation/nighttime-EE bump described above. The appetite-suppression effect can attenuate over time — a separate appetite-sensations analysis (Gilbert et al. 2012, n=158) found the satiety increase peaked around 12 weeks and faded by 24 weeks even though weight loss continued `` (PMID 21720440, not independently confirmed this pass).

Tesomet (the metoprolol combination) — hypothalamic obesity (PMID 35294397, Huynh et al., Eur J Endocrinol 2022): a small but clean trial, n=21 adults with hypothalamic obesity (a hard-to-treat obesity caused by hypothalamic damage), 24 weeks. Tesomet produced 6.3% additional weight loss vs placebo (95% CI −11.3 to −1.3; p=0.017), and 8 of 13 on Tesomet hit ≥5% weight loss vs 1 of 8 on placebo. This is the rare-disease lane Saniona has prioritized (Tesomet also has FDA orphan-drug designations in hypothalamic obesity and Prader-Willi syndrome).

Abuse-potential check (PMID 20520602, Schoedel et al. 2010): n=52 recreational stimulant users. Despite being a dopamine-active drug, tesofensine’s subjective effects were not significantly different from placebo and far below D-amphetamine — comparable to bupropion and atomoxetine (both unscheduled). The authors concluded it’s “unlikely to be recreationally abused.” Useful counterweight to the assumption that a triple-monoamine drug must be a problematic stimulant.

The neurological trials it failed (important context, not failures of the weight mechanism):

• Parkinson’s disease — Hauser et al. 2007 (early PD, n=261): NS 2330 gave no significant benefit over placebo (PMID 17149725). Rascol et al. 2008 (advanced PD, the ADVANS study): only modest motor improvements `` (PMID 18474731).
• Alzheimer’s disease — a Phase 2b trial was predicted to fail by PK/PD modeling and did not pan out `` (PMID 20077053). Tesofensine is not an effective dementia drug; the cognitive effect it does have is stimulant-class alertness, not disease modification.

Where the data points: tesofensine is the best-evidenced oral, non-GLP-1 weight-loss drug — strong Phase 2 obesity efficacy (~9–11% at 24 weeks), a coherent mechanism, and a clean abuse-potential profile. Its honest limitations: it never reached Phase 3 in general obesity, its appetite effect may attenuate over months, and it carries a real cardiovascular signal that reshaped its entire development path. The GLP-1 class (Tirzepatide ~21%, Retatrutide higher still — see The 2026 GLP-1 pipeline — Dulaglutide, Liraglutide, Semaglutide, Tirzepatide, CagriSema, Mazdutide, MariTide, Pemvidutide, Petrelintide, VK2735, Orforglipron, Survodutide, Eloralintide, Retatrutide) has overtaken tesofensine’s standalone numbers, but the oral route and distinct mechanism keep it relevant.

Where experts disagree

• “Stalled for safety” vs “stalled for strategy.” One reading (the cautious one): tesofensine’s cardiovascular signal is a real reason it never became a mainstream obesity drug, and the GLP-1s rightly leapfrogged it. The other reading: the BP/HR rise is small and manageable (Saniona’s own fix — adding generic metoprolol — is cheap and effective), and the standalone drug’s stall had as much to do with the company’s pivot toward rare-disease orphan indications (where the economics and regulatory path were cleaner) as with the molecule being unsafe. Both are partly true. The honest synthesis: the cardiovascular effect is genuine and disqualifies tesofensine as a casual self-administered tool, but it’s a manageable signal, not a dangerous one — which is exactly why the combination product exists.
• Is the secondary “mind” effect a feature or a flag? Because it raises dopamine and noradrenaline, some frame tesofensine’s alertness/drive effect as a bonus (focus + appetite control in one). Others (the more cautious read, and the one the categorization pass leans toward) treat the CNS-stimulant character as the source of the cardiovascular risk, not a free perk. OHM’s position: the cognitive lift is real but it’s the same pharmacology that raises your heart rate — they’re not separable, so don’t chase one while ignoring the other.

Real-world protocol

The doses and schedules here are for educational and informational purposes only. Tesofensine is not an FDA-approved drug; in the US it is sold only as a research chemical, “not for human consumption.” This is not medical advice. Consult a qualified physician before considering any protocol — and note that the cardiovascular profile makes baseline blood-pressure and heart-rate awareness genuinely relevant here, more so than for most peptides on this site.

Route. Oral, once daily — this is the practical selling point. No reconstitution, no injection, no insulin syringe. (That also means there’s no bacteriostatic-water/dosing math the way there is for the injectable peptides elsewhere on this site.)

Doses studied in the obesity trials (for reference, not prescription):

• 0.25 mg/day — the low end; ~4.5% placebo-subtracted loss, smaller cardiovascular effect.
• 0.5 mg/day — the dose Astrup highlighted; ~9.2% loss. The efficacy/tolerability sweet spot in the trial data.
• 1.0 mg/day — top of the studied range; ~10.6% loss, but the largest BP/HR rise. The trials suggest diminishing returns relative to the added cardiovascular cost above 0.5 mg.

The cardiovascular caveat is the protocol. Unlike most molecules on this site, the central real-world consideration with tesofensine isn’t reconstitution or injection technique — it’s the heart-rate/blood-pressure rise. Anyone considering it should know their resting BP and HR, and the entire reason Saniona’s clinical version (Tesomet) adds metoprolol is to manage exactly this. People with hypertension, tachycardia, arrhythmia, or cardiovascular disease are the population where this drug’s risk concentrates.

Stacking / comparison, not stacking. Tesofensine is generally a standalone mechanism, not a stack component. The realistic comparison isn’t “tesofensine + X,” it’s “tesofensine vs a GLP-1.” If the appeal is oral dosing and a non-GLP-1 mechanism, tesofensine is the candidate; if maximum weight loss and the best Phase 3 evidence are the priority, the GLP-1 class (Tirzepatide, Retatrutide) is ahead. The monoamine/cognitive overlap also makes Semax an interesting conceptual neighbor — a very different (and far gentler) molecule, but in the same “monoamines and the brain” conversation.

Side effects & management

• Cardiovascular — heart rate up to +8 bpm, blood pressure +1–5 mmHg (dose-dependent). The defining side effect and the one to actually respect. Know your baseline; this is the population where the drug is contraindicated if you have uncontrolled hypertension or significant cardiac disease.
• CNS-stimulant effects — given the dopamine/noradrenaline action, expect potential for insomnia (dose earlier in the day), jitteriness, dry mouth, and elevated alertness. The flip side of the “mind” benefit.
• Mood/serotonergic considerations — as a serotonin reuptake inhibitor, tesofensine has the theoretical interaction profile of serotonergic drugs (caution with SSRIs/SNRIs/MAOIs; serotonin-syndrome risk in combination). Not characterized in the captured source — flag for anyone on psychiatric medication.
• Appetite-effect attenuation — the satiety benefit may fade over months even as weight loss continues (PMID 21720440). Plan around the foundation (protein, resistance training, sleep), not the drug alone.
• Abuse potential — low (PMID 20520602). Reassuring given the mechanism: it does not produce amphetamine-like reinforcement.

The honest one-line risk read: tesofensine is an effective oral appetite suppressant whose entire safety story is cardiovascular. It’s not a forgiving, wide-margin molecule the way BPC-157 is — it’s a real pharmacological drug with a real, mechanism-linked cardiovascular signal. That doesn’t make it dangerous; it makes it a drug that deserves a blood-pressure cuff and a clear head, not casual experimentation.

Regulatory status

• United States: not FDA-approved for any indication. Sold only as a research chemical / “not for human consumption.” Not eligible for 503A/503B compounding. No legitimate prescription path in the US today.
• Mexico: filed, not yet approved. Saniona’s partner Medix received a favorable opinion from the COFEPRIS technical committee in February 2023 and filed the new-drug application; as of Saniona’s 2024 disclosures the agency had no further questions and a final decision was pending. So “approved in Mexico” is premature — it’s under review, the furthest along of any market.
• Combination product (Tesomet) holds FDA orphan-drug designations in hypothalamic obesity and Prader-Willi syndrome — the rare-disease lane Saniona has prioritized over a general-obesity Phase 3.
• WADA: monoamine-reuptake stimulants are a class WADA scrutinizes; tesofensine’s specific status should be checked before competition use.

How to access it

Tesofensine is not something this site can point you to a clean, verified source for — and that’s the honest answer. It’s an investigational/prescription pharmaceutical, not a research-use-only catalog peptide. There is no Alyve product, no verified-vendor affiliate path, and no OHM coupon for tesofensine, because it doesn’t sit in the verified-supply lane that the catalog peptides do.

The reality of the supply landscape:

1. No legitimate US prescription route exists — it’s not FDA-approved and not compoundable, so a US clinician can’t lawfully prescribe it.
2. The only approved-market path is outside the US — and even there, tesofensine is still awaiting final approval in Mexico (its furthest-along market), not yet on shelves.
3. The gray market sells it as a “research chemical” — the online vendors that list it are the same unverified research-peptide tier that independent testing repeatedly finds underdosed, mislabeled, or contaminated, often with no certificate of analysis (COA) at all. For a drug whose entire risk profile is cardiovascular, taking an unverified-purity version is exactly the wrong place to gamble on what’s actually in the vial.

The honest bottom line: for a US-based reader, there is no clean way to obtain pharmaceutical-grade tesofensine right now. That’s not a sales redirect — it’s the actual state of the molecule. If and when Tesomet clears its approval path (Mexico first, possibly rare-disease indications via Saniona’s orphan track), legitimate access would come through a clinician and a real pharmacy, the same way Tirzepatide’s legitimate supply does — not through a “research” website. Until then, tesofensine is better understood than obtained: a well-studied oral mechanism worth knowing about as you weigh it against the GLP-1 class, not a product to chase.

Sources

• thepeptidelist.com directory capture (facts/citations only; site prose not reproduced). Source of the 10 key-study citations, the benefit/study-count table, the FDA research_only status, and the ClinicalTrials.gov trial list.
• underlying structured capture (clinicaltrials.gov: 13 trials, 11 Phase 2, n≈1,513; top conditions: obesity, Parkinson’s, Prader-Willi, T2D).
• tesofensine B/yellow, PRIMARY lose-weight + SECONDARY mind grading; “Saniona revival in Prader-Willi + hypothalamic obesity” + cardiovascular-yellow rationale.
• Web-verified primary literature (PubMed): PMID 18950853 (Astrup, Lancet 2008, obesity Phase 2); PMID 35294397 (Huynh, Eur J Endocrinol 2022, Tesomet hypothalamic obesity); PMID 20479765 (Sjödin, Int J Obes 2010, energy metabolism); PMID 20520602 (Schoedel, Clin Pharmacol Ther 2010, abuse potential); PMID 19824222 (Nielsen 2009, secondary publication); PMID 17149725 (Hauser 2007, Parkinson’s).
• Saniona pipeline disclosures (saniona.com; BioStock 2023–2024 coverage) — Tesomet = tesofensine + metoprolol; metoprolol added to mitigate BP/HR; Medix/Mexico COFEPRIS favorable opinion Feb 2023, filing May 2023, awaiting final approval as of 2024.

Related: The 2026 GLP-1 pipeline — Dulaglutide, Liraglutide, Semaglutide, Tirzepatide, CagriSema, Mazdutide, MariTide, Pemvidutide, Petrelintide, VK2735, Orforglipron, Survodutide, Eloralintide, Retatrutide · Retatrutide · Tirzepatide · Semax · Semaglutide · Cagrilintide.